XenoTech, MultiCell Licensee, Presents Cell Lines at 7th Annual ISSX Meeting.
XenoTech will emphasize the role and potential of immortalized human hepatocytes in preclinical drug development. MultiCells's human hepatocyte lines can help solve the problem of supply and variability that restrict the use of harvested human liver cells for enzyme induction, cellular toxicity assays and other in vitro screening. Two abstracts will be presented Tuesday:
Abstract #378 Induction of UDP-glucuronosyltransferases in primary cultures and immortalized hepatocytes.
Abstract #367 Cytochrome P450 3A4 and 1A2 induction in the immortalized hepatocyte line, Fa2N-4, and comparison with primary cultures of human hepatocytes.
Hepatocytes metabolize or detoxify drugs or substances ingested into the body. Drug failures or FDA rejections due to hepatotoxicity and/or drug-drug interactions now cost the pharmaceutical industry an estimated $2 billion each year. It costs about $900 million to develop and test a new medicine.
MultiCell Technologies, Inc. provides non-tumorigenic functional hepatic (liver) cells and cell lines plated (6 to 96 wells) or in vials to pharmaceutical companies for drug discovery. For pricing and delivery information, contact XenoTech, LLC of Lenexa, KS, telephone 913-438-7450.
MultiCell's corporate and research headquarters are at 55 Access Road, Suite 700, in Warwick, Rhode Island. MultiCell's majority-owned Xenogenics subsidiary owns all rights to the Sybiol(TM) synthetic bio-liver device.
For more information about MultiCell and its Xenogenics subsidiary, call 401-738-7560 or see www.multicelltech.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 30, 2004|
|Previous Article:||Fitch Ratings Downgrades HarbourView CDO III.|
|Next Article:||Optical Solutions Secures FTTP Contract From All West Communications; All West Will Compete Against Incumbents with IPTV and 100+ Mbps Data Speeds.|